Payment overview · 2025
General Payments
$201.68
11 reported records · 8 companies
Healthcare provider profile · identity verified
Dennis D. Yap, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · SPRINGFIELD, IL · NPI 1508967597
Verified facts
What the public records show
CMS Open Payments records show Dennis D. Yap, M.D. received $201.68 in general payments during 2025 across 11 reported records.
E.R. Squibb & Sons, L.L.C. accounted for 25.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Ozempic.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Eliquis by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $51.98 | 25.8% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $33.95 | 16.8% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $31.33 | 15.5% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $18.74 | 9.3% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $18.59 | 9.2% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $16.88 | 8.4% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $16.58 | 8.2% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $13.63 | 6.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $201.68 | 11 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $51.98 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $33.95 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $33.95 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $31.33 | 2 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $18.74 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $18.74 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $18.59 | 1 | 2025 |
Source payment records
|
|||||
| WATCHMAN Access System Normalized: watchman access system |
Device | Boston Scientific Corporation | $16.88 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $16.58 | 1 | 2025 |
Source payment records
|
|||||
| Repatha Normalized: repatha |
Biological | Amgen Inc. | $13.63 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 77 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 49 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
77 | 20 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
49 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
77 | 20 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Lisinopril | Lisinopril | 339 | 92 |
| Amlodipine Besylate | Amlodipine Besylate | 261 | 70 |
| Atorvastatin Calcium | Atorvastatin Calcium | 261 | 76 |
| Levothyroxine Sodium | Levothyroxine Sodium | 229 | 53 |
| Metoprolol Succinate | Metoprolol Succinate | 222 | 64 |
| Omeprazole | Omeprazole | 189 | 46 |
| Tamsulosin Hcl | Tamsulosin Hcl | 188 | 43 |
| Losartan Potassium | Losartan Potassium | 156 | 41 |
| Prednisone | Prednisone | 137 | 85 |
| Hydrochlorothiazide | Hydrochlorothiazide | 131 | 42 |
| Glipizide Er | Glipizide | 111 | 29 |
| Clopidogrel | Clopidogrel Bisulfate | 98 | 20 |
| Furosemide | Furosemide | 92 | 31 |
| Fluoxetine Hcl | Fluoxetine Hcl | 89 | 23 |
| Carvedilol | Carvedilol | 84 | 20 |
| Gabapentin | Gabapentin | 83 | 29 |
| Metformin Hcl | Metformin Hcl | 79 | 26 |
| Eliquis | Apixaban | 77 | 20 |
| Tramadol Hcl | Tramadol Hcl | 77 | 17 |
| Metoprolol Tartrate | Metoprolol Tartrate | 76 | 24 |
| Allopurinol | Allopurinol | 75 | 21 |
| Pantoprazole Sodium | Pantoprazole Sodium | 73 | 23 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 72 | 28 |
| Simvastatin | Simvastatin | 72 | 19 |
| Januvia | Sitagliptin Phosphate | 67 | 17 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 67 | 16 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 66 | 38 |
| Montelukast Sodium | Montelukast Sodium | 66 | 24 |
| Azithromycin | Azithromycin | 65 | 50 |
| Cephalexin | Cephalexin | 60 | 52 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 55 | 17 |
| Duloxetine Hcl | Duloxetine Hcl | 54 | 14 |
| Pravastatin Sodium | Pravastatin Sodium | 54 | 14 |
| Sertraline Hcl | Sertraline Hcl | 54 | suppressed |
| Mirtazapine | Mirtazapine | 53 | 21 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 52 | 20 |
| Torsemide | Torsemide | 52 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 51 | suppressed |
| Bupropion Xl | Bupropion Hcl | 50 | 15 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 50 | 44 |
| Ozempic | Semaglutide | 49 | suppressed |
| Potassium Chloride | Potassium Chloride | 49 | 13 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 39 | suppressed |
| Spironolactone | Spironolactone | 39 | suppressed |
| Alprazolam | Alprazolam | 38 | 11 |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 35 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 33 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 33 | suppressed |
| Celecoxib | Celecoxib | 32 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 32 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 32 | suppressed |
| Jardiance | Empagliflozin | 32 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 30 | suppressed |
| Lovastatin | Lovastatin | 29 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 29 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 28 | suppressed |
| Entresto | Sacubitril/Valsartan | 28 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 28 | suppressed |
| Glipizide | Glipizide | 28 | suppressed |
| Olanzapine | Olanzapine | 27 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 27 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 27 | suppressed |
| Levofloxacin | Levofloxacin | 26 | 25 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 25 | 20 |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 23 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 23 | 18 |
| Ondansetron Odt | Ondansetron | 23 | suppressed |
| Fenofibrate | Fenofibrate | 21 | suppressed |
| Xarelto | Rivaroxaban | 21 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 20 | suppressed |
| Atenolol | Atenolol | 19 | suppressed |
| Fluconazole | Fluconazole | 19 | 13 |
| Diclofenac Sodium | Diclofenac Sodium | 18 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 18 | suppressed |
| Meloxicam | Meloxicam | 18 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 18 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 17 | suppressed |
| Ibuprofen | Ibuprofen | 17 | suppressed |
| Rybelsus | Semaglutide | 17 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 16 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 16 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 16 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 16 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 16 | suppressed |
| Famotidine | Famotidine | 15 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 14 | suppressed |
| Estradiol | Estradiol | 13 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Nystatin | Nystatin | 13 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 13 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 13 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 12 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 12 | suppressed |
| Dutasteride | Dutasteride | 12 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 12 | suppressed |
| Levetiracetam | Levetiracetam | 12 | suppressed |
| Lorazepam | Lorazepam | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Risperidone | Risperidone | 12 | suppressed |
| Trueplus Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 11 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $201.68 · 11 records | E.R. Squibb & Sons, L.L.C. | CREON, ELIQUIS, FARXIGA, LINZESS, NURTEC ODT, Ozempic, Repatha, VOQUEZNA, WATCHMAN Access System, ZAVZPRET | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with E.R. Squibb & Sons, L.L.C.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error